Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase ...
Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...
Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC). Validation of the association of RECIST ...
PHILADELPHIA, June 29, 2021 /PRNewswire/ — Signant Health, the leader in evidence generation for modern clinical trials, today announced a new acceleration program that reduces study setup timelines ...
Central nervous system (CNS) clinical trials are among the most scientifically complex and operationally demanding in life sciences. The need to evaluate nuanced cognitive, behavioral, and emotional ...
Service ensures that clinicians are properly qualified, consistently trained and monitored throughout the life of a trialMAIDENHEAD, England--(BUSINESS WIRE)--RWS (RWS.L), a global AI solutions ...
Primary central nervous system (CNS) vasculitis is a rare, frequently misdiagnosed condition that affects the brain and spinal cord and is characterized by a variety of neurologic symptoms at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results